New drugs for methicillin-resistant Staphylococcus aureus: an update

TD-1792 versus Vancomycin for Treatment of Complicated Skin and Skin Structure Infections

(2012) Martin E. Stryjewski et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mode of Action,In VitroActivity, andIn VivoEfficacy of AFN-1252, a Selective Antistaphylococcal FabI Inhibitor

(2012) Nachum Kaplan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Randomized, Evaluator-Blind, Phase 2 Study Comparing the Safety and Efficacy of Omadacycline to Those of Linezolid for Treatment of Complicated Skin and Skin Structure Infections

(2012) Gary J. Noel et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Target- and Resistance-Based Mechanistic Studies with TP-434, a Novel Fluorocycline Antibiotic

(2012) Trudy H. Grossman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization

(2012) J. M. Remy et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Antibiotics in development targeting protein synthesis

(2011) Joyce A. Sutcliffe   Annals of the New York Academy of Sciences

The oxazolidinones: past, present, and future

(2011) Karen Joy Shaw et al.   Annals of the New York Academy of Sciences

Tripropeptin C Blocks the Lipid Cycle of Cell Wall Biosynthesis by Complex Formation with Undecaprenyl Pyrophosphate

(2011) Hideki Hashizume et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antistaphylococcal Activity of TD-1792, a Multivalent Glycopeptide-Cephalosporin Antibiotic

(2011) Johanne Blais et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Randomized, Double-Blind, Phase II, Multicenter Study Evaluating the Safety/Tolerability and Efficacy of JNJ-Q2, a Novel Fluoroquinolone, Compared with Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infection

(2011) Paul Covington et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

JNJ-Q2, a New Fluoroquinolone with PotentIn VitroActivity against Staphylococcus aureus, Including Methicillin- and Fluoroquinolone-Resistant Strains

(2011) David J. Farrell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of a New Fluoroquinolone, JNJ-Q2, in Murine Models of Staphylococcus aureus and Streptococcus pneumoniae Skin, Respiratory, and Systemic Infections

(2011) Jeffrey Fernandez et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Oritavancin Activity against Vancomycin-Susceptible and Vancomycin-Resistant Enterococci with Molecularly Characterized Glycopeptide Resistance Genes Recovered from Bacteremic Patients, 2009-2010

(2011) Rodrigo E. Mendes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mechanism of Action and Limited Cross-Resistance of New Lipopeptide MX-2401

(2011) E. Rubinchik et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro and In Vivo Profiles of ACH-702, an Isothiazoloquinolone, against Bacterial Pathogens

(2011) Michael J. Pucci et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The MUT056399 Inhibitor of FabI Is a New Antistaphylococcal Compound

(2011) S. Escaich et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparison of the Efficacy and Safety of Oritavancin Front-Loaded Dosing Regimens to Daily Dosing: an Analysis of the SIMPLIFI Trial

(2011) Lala M. Dunbar et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroSpectrum of Activity of Finafloxacin, a Novel, pH-Activated Fluoroquinolone, under Standard and Acidic Conditions

(2011) Will Stubbings et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Solid state of CG-400549, a novel FabI inhibitor: Characterization, dissolution, transformation

(2011) Bo-Yeon Kim et al.   ARCHIVES OF PHARMACAL RESEARCH

New Gram-positive antibiotics

(2011) Sebastiaan J. van Hal et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Activity of ACHN-490 against meticillin-resistant Staphylococcus aureus (MRSA) isolates from patients in US hospitals

(2011) Fred C. Tenover et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Comparative in vitro activity of finafloxacin against staphylococci displaying normal and small colony variant phenotypes

(2011) Evgeny A. Idelevich et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Determination of Disk Diffusion and MIC Quality Control Ranges for GSK1322322, a Novel Peptide Deformylase Inhibitor

(2011) James E. Ross et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Fluorocyclines. 1. 7-Fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: A Potent, Broad Spectrum Antibacterial Agent

(2011) Xiao-Yi Xiao et al.   JOURNAL OF MEDICINAL CHEMISTRY

The mechanism of action of sanguinarine against methicillin-resistant Staphylococcus aureus

(2011) Brice W Obiang-Obounou et al.   JOURNAL OF TOXICOLOGICAL SCIENCES

In Vivo Pharmacodynamics of New Lipopeptide MX-2401

(2010) W. A. Craig et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Structure-Activity Relationships of Diverse Oxazolidinones for Linezolid-Resistant Staphylococcus aureus Strains Possessing the cfr Methyltransferase Gene or Ribosomal Mutations

(2010) J. B. Locke et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of the New Multivalent Glycopeptide-Cephalosporin Antibiotic TD-1792 against Vancomycin-Nonsusceptible Staphylococcus Isolates

(2010) K. D. Leuthner et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Phase 2, Randomized, Double-Blind, Dose-Ranging Study Evaluating the Safety, Tolerability, Population Pharmacokinetics, and Efficacy of Oral Torezolid Phosphate in Patients with Complicated Skin and Skin Structure Infections

(2010) P. Prokocimer et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Investigation of the Potential for Mutational Resistance to XF-73, Retapamulin, Mupirocin, Fusidic Acid, Daptomycin, and Vancomycin in Methicillin-ResistantStaphylococcus aureusIsolates during a 55-Passage Study

(2010) David J. Farrell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The 10 × ‘20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020

(2010)   CLINICAL INFECTIOUS DISEASES

New aminoglycoside antibiotics

(2010) Paola Dozzo et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

In vitro activity of XF-73, a novel antibacterial agent, against antibiotic-sensitive and -resistant Gram-positive and Gram-negative bacterial species

(2010) David J. Farrell et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Activity of moxifloxacin against intracellular community-acquired methicillin-resistant Staphylococcus aureus: comparison with clindamycin, linezolid and co-trimoxazole and attempt at defining an intracellular susceptibility breakpoint

(2010) S. Lemaire et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Essentiality of FASII pathway for Staphylococcus aureus

(2010) Wendy Balemans et al.   NATURE

Inhibitory properties and X-ray crystallographic study of the binding of AR-101, AR-102 and iclaprim in ternary complexes with NADPH and dihydrofolate reductase fromStaphylococcus aureus

(2009) Christian Oefner et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Multicenter, Randomized Study of the Efficacy and Safety of Intravenous Iclaprim in Complicated Skin and Skin Structure Infections

(2009) D. Krievins et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

AFN-1252, a FabI Inhibitor, Demonstrates a Staphylococcus-Specific Spectrum of Activity

(2009) J. A. Karlowsky et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

XF-70 and XF-73, novel antibacterial agents active against slow-growing and non-dividing cultures of Staphylococcus aureus including biofilms

(2009) N. Ooi et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity

(2009) C. Oefner et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In Vitro Activities of the Rx-01 Oxazolidinones against Hospital and Community Pathogens

(2008) L. Lawrence et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of the Quinolone WCK 771 against Recent U.S. Hospital and Community-Acquired Staphylococcus aureus Pathogens with Various Resistance Types

(2008) S. S. Bhagwat et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of TR-700, the Antibacterial Moiety of the Prodrug TR-701, against Linezolid-Resistant Strains

(2008) K. J. Shaw et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Oritavancin Kills Stationary-Phase and Biofilm Staphylococcus aureus Cells In Vitro

(2008) A. Belley et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Crystal Structure of the Oxazolidinone Antibiotic Linezolid Bound to the 50S Ribosomal Subunit∥

(2008) Joseph A. Ippolito et al.   JOURNAL OF MEDICINAL CHEMISTRY

Oritavancin Exhibits Dual Mode of Action to Inhibit Cell-Wall Biosynthesis in Staphylococcus aureus

(2008) Sung Joon Kim et al.   JOURNAL OF MOLECULAR BIOLOGY